India Pharma Outlook Team | Thursday, 10 September 2026
Natco Pharma is preparing to strengthen its financial capacity as it evaluates new opportunities for expansion through acquisitions.
The company’s board has approved a proposal to raise up to Rs 1,300 crore through a rights issue of equity shares, adding another funding route to its existing capital-raising plans. The move comes at a time when Natco Pharma is assessing potential M&A opportunities and building greater financial flexibility to pursue them.
The proposed rights issue, alongside the company’s earlier Rs 2,000-crore QIP plan and substantial internal cash reserves, could give the pharmaceutical company a sizeable pool of capital for strategic investments and acquisitions.
The latest fundraising plan involves issuing equity shares with a face value of Rs 2 each through a rights issue. While the board has approved the proposal, the company’s broader capital strategy already includes a planned Rs 2,000-crore fundraise through a Qualified Institutional Placement (QIP).
The additional capital could strengthen Natco Pharma’s balance sheet as it considers acquisitions in the pharmaceutical sector. The company has around Rs 3,500 crore in internal cash reserves, providing another source of funding for potential transactions.
The combination of internal resources and external fundraising could give Natco greater flexibility when evaluating acquisition targets. Rather than depending solely on its existing cash position, the company can potentially deploy a broader capital base across multiple opportunities.
For pharmaceutical companies, acquisitions can provide faster access to products, technologies, intellectual property and new markets than developing these capabilities entirely in-house. Natco’s fundraising strategy appears closely connected to its plans to expand through strategic M&A while retaining sufficient financial flexibility for its existing operations.
Natco Pharma’s management has already indicated that acquisitions are an important part of its growth strategy. During the company’s first-quarter FY27 earnings call, CEO Rajeev Nannapaneni told analysts that Natco had identified “a few interesting M&A opportunities” and intended to use the new funding option to execute those buyouts.
The statement provides greater context to the Rs 1,300-crore rights issue. The fundraising is not simply about increasing liquidity; it could support Natco Pharma’s acquisition pipeline at a time when the company is actively assessing potential targets.
A larger funding pool could also improve the company’s ability to respond when suitable M&A opportunities emerge. Pharmaceutical acquisitions often require significant upfront capital, particularly when transactions involve established products, specialised portfolios or strategic market access.
Natco Pharma’s capital-raising plans could consequently position the company to move faster when acquisition opportunities align with its business priorities. The rights issue and proposed QIP, backed by internal cash reserves, together indicate a deliberate effort to build acquisition capacity.
The key focus now will be on how Natco deploys the capital and whether the identified M&A opportunities translate into completed transactions. For investors, the eventual size, structure and strategic value of these acquisitions will be important in determining whether the fundraising delivers meaningful long-term growth.
